BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Edvinsson L, Warfvinge K. Recognizing the role of CGRP and CGRP receptors in migraine and its treatment. Cephalalgia 2019;39:366-73. [DOI: 10.1177/0333102417736900] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 8.2] [Reference Citation Analysis]
Number Citing Articles
1 Moreno-Ajona D, Hoffmann J. From basic mechanisms to therapeutic perspectives in cluster headache. Curr Opin Neurol 2022;35:336-42. [PMID: 35674077 DOI: 10.1097/WCO.0000000000001055] [Reference Citation Analysis]
2 Urits I, Clark G, An D, Wesp B, Zhou R, Amgalan A, Berger AA, Kassem H, Ngo AL, Kaye AD, Kaye RJ, Cornett EM, Viswanath O. An Evidence-Based Review of Fremanezumab for the Treatment of Migraine. Pain Ther 2020;9:195-215. [PMID: 32222952 DOI: 10.1007/s40122-020-00159-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
3 Borkum JM. CGRP and Brain Functioning: Cautions for Migraine Treatment. Headache: The Journal of Head and Face Pain 2019;59:1339-57. [DOI: 10.1111/head.13591] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
4 Arca K, Reynolds J, Sands KA, Shiue HJ. Calcitonin Gene-Related Peptide Antagonists for the Prevention of Migraine: Highlights From Pivotal Studies and the Clinical Relevance of This New Drug Class. Ann Pharmacother 2020;54:795-803. [DOI: 10.1177/1060028020903417] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Casillo F, Sebastianelli G, Renzo AD, Cioffi E, Parisi V, Lorenzo CD, Serrao M, Coppola G. The monoclonal CGRP-receptor blocking antibody erenumab has different effects on brainstem and cortical sensory-evoked responses. Cephalalgia. [DOI: 10.1177/03331024221103811] [Reference Citation Analysis]
6 Marichal-Cancino BA, González-Hernández A, Guerrero-Alba R, Medina-Santillán R, Villalón CM. A critical review of the neurovascular nature of migraine and the main mechanisms of action of prophylactic antimigraine medications. Expert Rev Neurother 2021;:1-16. [PMID: 34388955 DOI: 10.1080/14737175.2021.1968835] [Reference Citation Analysis]
7 Tarperi C, Sanchis-gomar F, Montagnana M, Danese E, Salvagno GL, Gelati M, Skroce K, Schena F, Lippi G. Effects of endurance exercise on serum concentration of calcitonin gene-related peptide (CGRP): a potential link between exercise intensity and headache. Clinical Chemistry and Laboratory Medicine (CCLM) 2020;58:1707-12. [DOI: 10.1515/cclm-2019-1337] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Moreno-Ajona D, Pérez-Rodríguez A, Goadsby PJ. Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment? Curr Opin Neurol 2020;33:309-15. [PMID: 32251023 DOI: 10.1097/WCO.0000000000000806] [Cited by in Crossref: 23] [Cited by in F6Publishing: 7] [Article Influence: 23.0] [Reference Citation Analysis]
9 Wattiez AS, Sowers LP, Russo AF. Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting. Expert Opin Ther Targets 2020;24:91-100. [PMID: 32003253 DOI: 10.1080/14728222.2020.1724285] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
10 Alpuente A, Gallardo VJ, Asskour L, Caronna E, Torres-Ferrus M, Pozo-Rosich P. Salivary CGRP can monitor the different migraine phases: CGRP (in)dependent attacks. Cephalalgia 2021;:3331024211040467. [PMID: 34601944 DOI: 10.1177/03331024211040467] [Reference Citation Analysis]
11 Johnson KW, Morin SM, Wroblewski VJ, Johnson MP. Peripheral and central nervous system distribution of the CGRP neutralizing antibody [ 125 I] galcanezumab in male rats. Cephalalgia 2019;39:1241-8. [DOI: 10.1177/0333102419844711] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 10.3] [Reference Citation Analysis]
12 De Logu F, Nassini R, Landini L, Geppetti P. Pathways of CGRP Release from Primary Sensory Neurons. Handb Exp Pharmacol 2019;255:65-84. [PMID: 29980913 DOI: 10.1007/164_2018_145] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
13 Ceriani CEJ, Wilhour DA, Silberstein SD. Novel Medications for the Treatment of Migraine. Headache: The Journal of Head and Face Pain 2019;59:1597-608. [DOI: 10.1111/head.13661] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
14 Serafin DS, Harris NR, Nielsen NR, Mackie DI, Caron KM. Dawn of a New RAMPage. Trends Pharmacol Sci 2020;41:249-65. [PMID: 32115276 DOI: 10.1016/j.tips.2020.01.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
15 Coppola G, Pierelli F, Schoenen J, Wang S, Chen W. Neurophysiological Model of Migraine Pathophysiology: Bringing the Past into the Future. In: Coppola G, Chen W, editors. Neurophysiology of the Migraine Brain. Cham: Springer International Publishing; 2021. pp. 223-36. [DOI: 10.1007/978-3-030-56538-1_17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Rustichelli C, Avallone R, Ferrari A. Atogepant: an emerging treatment for migraine. Expert Opin Pharmacother 2022;:1-10. [PMID: 35319319 DOI: 10.1080/14656566.2022.2057221] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Ornello R, Frattale I, Caponnetto V, Pistoia F, Sacco S. Cerebral vascular reactivity and the migraine-stroke relationship: A narrative review. J Neurol Sci 2020;414:116887. [PMID: 32407982 DOI: 10.1016/j.jns.2020.116887] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
18 Ornello R, Frattale I, Caponnetto V, De Matteis E, Pistoia F, Sacco S. Menstrual Headache in Women with Chronic Migraine Treated with Erenumab: An Observational Case Series. Brain Sci 2021;11:370. [PMID: 33805838 DOI: 10.3390/brainsci11030370] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
19 Szperka CL, VanderPluym J, Orr SL, Oakley CB, Qubty W, Patniyot I, Lagman-Bartolome AM, Morris C, Gautreaux J, Victorio MC, Hagler S, Narula S, Candee MS, Cleves-Bayon C, Rao R, Fryer RH, Bicknese AR, Yonker M, Hershey AD, Powers SW, Goadsby PJ, Gelfand AA. Recommendations on the Use of Anti-CGRP Monoclonal Antibodies in Children and Adolescents. Headache 2018;58:1658-69. [PMID: 30324723 DOI: 10.1111/head.13414] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
20 Iyengar S, Johnson KW, Ossipov MH, Aurora SK. CGRP and the Trigeminal System in Migraine. Headache 2019;59:659-81. [PMID: 30982963 DOI: 10.1111/head.13529] [Cited by in Crossref: 71] [Cited by in F6Publishing: 62] [Article Influence: 23.7] [Reference Citation Analysis]
21 Dux M, Rosta J, Messlinger K. TRP Channels in the Focus of Trigeminal Nociceptor Sensitization Contributing to Primary Headaches. Int J Mol Sci 2020;21:E342. [PMID: 31948011 DOI: 10.3390/ijms21010342] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
22 Raut S, Singh U, Sarmah D, Datta A, Baidya F, Shah B, Bohra M, Jagtap P, Sarkar A, Kalia K, Borah A, Dave KR, Yavagal DR, Bhattacharya P. Migraine and Ischemic Stroke: Deciphering the Bidirectional Pathway. ACS Chem Neurosci 2020;11:1525-38. [PMID: 32348103 DOI: 10.1021/acschemneuro.0c00137] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
23 Edvinsson L. The CGRP Pathway in Migraine as a Viable Target for Therapies. Headache 2018;58 Suppl 1:33-47. [PMID: 29697153 DOI: 10.1111/head.13305] [Cited by in Crossref: 40] [Cited by in F6Publishing: 29] [Article Influence: 13.3] [Reference Citation Analysis]
24 Moreno-ajona D, Pérez-rodríguez A, Goadsby PJ. Small-molecule CGRP receptor antagonists: A new approach to the acute and preventive treatment of migraine. Medicine in Drug Discovery 2020;7:100053. [DOI: 10.1016/j.medidd.2020.100053] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Orlova YY, Mehla S, Chua AL. Drug Safety in Episodic Migraine Management in Adults Part 1: Acute Treatments. Curr Pain Headache Rep 2022. [PMID: 35536501 DOI: 10.1007/s11916-022-01057-3] [Reference Citation Analysis]
26 Favoni V, Giani L, Al-Hassany L, Asioli GM, Butera C, de Boer I, Guglielmetti M, Koniari C, Mavridis T, Vaikjärv M, Verhagen I, Verzina A, Zick B, Martelletti P, Sacco S; European Headache Federation School of Advanced Studies (EHF-SAS). CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP? J Headache Pain 2019;20:27. [PMID: 30866804 DOI: 10.1186/s10194-019-0979-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 10.3] [Reference Citation Analysis]
27 Chiang CC, Shahid AH, Harriott AM, Tietjen GE, Savastano LE, Klaas JP, Lanzino G. Evaluation and treatment of headache associated with moyamoya disease - a narrative review. Cephalalgia 2021;:3331024211056250. [PMID: 34786968 DOI: 10.1177/03331024211056250] [Reference Citation Analysis]
28 Liu Y, Chen QY, Lee JH, Li XH, Yu S, Zhuo M. Cortical potentiation induced by calcitonin gene-related peptide (CGRP) in the insular cortex of adult mice. Mol Brain 2020;13:36. [PMID: 32151282 DOI: 10.1186/s13041-020-00580-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
29 Warfvinge K, Edvinsson L. Cellular distribution of PACAP-38 and PACAP receptors in the rat brain: Relation to migraine activated regions. Cephalalgia 2020;40:527-42. [DOI: 10.1177/0333102419893962] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
30 Romo-Nava F, Blom T, Cuellar-Barboza AB, Awosika OO, Martens BE, Mori NN, Colby CL, Prieto ML, Veldic M, Singh B, Gardea-Resendez M, Nunez NA, Ozerdem A, Biernacka JM, Frye MA, McElroy SL. Revisiting the bipolar disorder with migraine phenotype: Clinical features and comorbidity. J Affect Disord 2021;295:156-62. [PMID: 34464877 DOI: 10.1016/j.jad.2021.08.026] [Reference Citation Analysis]
31 Eller M, Goadsby PJ. Migraine: a brain state amenable to therapy. Med J Aust 2020;212:32-9. [PMID: 31808561 DOI: 10.5694/mja2.50435] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
32 Tiseo C, Ornello R, Pistoia F, Sacco S. How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practice. J Headache Pain 2019;20:49. [PMID: 31060490 DOI: 10.1186/s10194-019-1000-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 8.3] [Reference Citation Analysis]
33 Dodick DW, Lipton RB, Ailani J, Halker Singh RB, Shewale AR, Zhao S, Trugman JM, Yu SY, Viswanathan HN. Ubrogepant, an Acute Treatment for Migraine, Improved Patient-Reported Functional Disability and Satisfaction in 2 Single-Attack Phase 3 Randomized Trials, ACHIEVE I and II. Headache 2020;60:686-700. [PMID: 32073660 DOI: 10.1111/head.13766] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 9.5] [Reference Citation Analysis]
34 Lee MJ, Lee SY, Cho S, Kang ES, Chung CS. Feasibility of serum CGRP measurement as a biomarker of chronic migraine: a critical reappraisal. J Headache Pain 2018;19:53. [PMID: 30006780 DOI: 10.1186/s10194-018-0883-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
35 Harder AVE, Vijfhuizen LS, Henneman P, Willems van Dijk K, van Duijn CM, Terwindt GM, van den Maagdenberg AMJM. Metabolic profile changes in serum of migraine patients detected using 1H-NMR spectroscopy. J Headache Pain 2021;22:142. [PMID: 34819016 DOI: 10.1186/s10194-021-01357-w] [Reference Citation Analysis]
36 Villar-Martínez MD, Moreno-Ajona D, Goadsby PJ. Eptinezumab for the preventive treatment of migraine. Pain Manag 2021;11:113-21. [PMID: 33280422 DOI: 10.2217/pmt-2020-0075] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Pellitteri G, Pez S, Nilo A, Surcinelli A, Gigli GL, Lettieri C, Valente M. Erenumab Impact on Sleep Assessed With Questionnaires and Home-Polysomnography in Patients With Migraine: The ERESON Study. Front Neurol 2022;13:869677. [DOI: 10.3389/fneur.2022.869677] [Reference Citation Analysis]
38 Zhang Y, Zhang Y, Tian K, Wang Y, Fan X, Pan Q, Qin G, Zhang D, Chen L, Zhou J. Calcitonin gene-related peptide facilitates sensitization of the vestibular nucleus in a rat model of chronic migraine. J Headache Pain 2020;21:72. [PMID: 32522232 DOI: 10.1186/s10194-020-01145-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
39 Hong P, Tan T, Liu Y, Xiao J. Gepants for abortive treatment of migraine: A network meta-analysis. Brain Behav 2020;10:e01701. [PMID: 32525262 DOI: 10.1002/brb3.1701] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
40 Farhangi M, Diel RJ, Buse DC, Huang AM, Levitt RC, Sarantopoulos CD, Felix ER, Galor A. Individuals with migraine have a different dry eye symptom profile than individuals without migraine. Br J Ophthalmol 2020;104:260-4. [PMID: 31040130 DOI: 10.1136/bjophthalmol-2018-313471] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
41 Hong P, Liu Y, Wan Y, Xiong H, Xu Y. Transcranial direct current stimulation for migraine: a systematic review and meta-analysis of randomized controlled trials. CNS Neurosci Ther 2022;28:992-8. [PMID: 35437933 DOI: 10.1111/cns.13843] [Reference Citation Analysis]
42 Edvinsson L, Haanes KA. Views on migraine pathophysiology: Where does it start? Neurol Clin Neurosci 2020;8:120-7. [DOI: 10.1111/ncn3.12356] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
43 Noor N, Angelette A, Lawson A, Patel A, Urits I, Viswanath O, Yazdi C, Kaye AD. A Comprehensive Review of Zavegepant as Abortive Treatment for Migraine. Health Psychol Res 2022;10:35506. [PMID: 35774914 DOI: 10.52965/001c.35506] [Reference Citation Analysis]
44 Ng CYH, Tan BYQ, Teo YN, Teo YH, Syn NLX, Leow AST, Ho JSY, Chan MY, Wong RCC, Chai P, Chan ACY, Sharma VK, Yeo LLL, Sia CH, Ong JJY. Myocardial infarction, stroke and cardiovascular mortality among migraine patients: a systematic review and meta-analysis. J Neurol 2022. [PMID: 34997286 DOI: 10.1007/s00415-021-10930-x] [Reference Citation Analysis]
45 Wang L, Fu LL, Deng ZR, Zhang J, Zu MD, Wu JC, Wang Y. Overexpression of BDNF in the ventrolateral periaqueductal gray regulates the behavior of epilepsy-migraine comorbid rats. Brain Behav 2022;:e2594. [PMID: 35557046 DOI: 10.1002/brb3.2594] [Reference Citation Analysis]
46 Goadsby PJ, Tepper SJ, Watkins PB, Ayele G, Miceli R, Butler M, Severt L, Finnegan M, Szegedi A, Trugman JM, Jakate A. Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults. Cephalalgia 2019;39:1753-61. [PMID: 31537107 DOI: 10.1177/0333102419869918] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 6.7] [Reference Citation Analysis]
47 Serra López-Matencio JM, Gago-Veiga AB, Gómez M, Alañón-Plaza E, Mejía GP, González-Gay MÁ, Castañeda S. Treatment of migraine with monoclonal antibodies. Expert Opin Biol Ther 2022. [PMID: 35502612 DOI: 10.1080/14712598.2022.2072207] [Reference Citation Analysis]